Key facts
- This page summarizes Timothy P. Clackson's Form 3 filing for Xilio Therapeutics, Inc. (XLO).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 21 Oct 2021, 20:52.
Timothy P. Clackson - 21 Oct 2021 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- XLO
- Reported as of
- 21 Oct 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 21 Oct 2021, 20:52:26 UTC
- Prior SEC filing
- 06 Oct 2021
- Next SEC filing
- 22 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Timothy Clackson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Timothy P. Clackson filed Form 3 for Xilio Therapeutics, Inc. (XLO) on 21 Oct 2021.
Change
- Previous filing in this sequence was filed on 06 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XLO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,068
- Date
- 21 Oct 2021
- Ownership
- Direct
XLO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 70,888
- Date
- 21 Oct 2021
- Ownership
- The Timothy P. Clackson Irrevocable GST Trust of 2020
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XLO
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 21 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,525
- Exercise price
- $5.51
- Footnotes
- F1
XLO
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 21 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,776
- Exercise price
- $5.51
- Footnotes
- F2
XLO
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 21 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,281
- Exercise price
- $5.51
- Footnotes
- F3
XLO
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 21 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,213
- Exercise price
- $5.89
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The option was granted on July 23, 2020 for 32,846 shares. On May 21, 2019, 25% of the shares underlying the option vested and the remaining shares shall vest in equal monthly installments until May 21, 2022.
Footnote F2
The option was granted on July 23, 2020 for 11,104 shares. On June 14, 2020, 25% of the shares underlying the option vested and the remainder shall vest in equal monthly installments thereafter until June 14, 2023.
Footnote F3
The option was granted on July 23, 2020 for 23,045 shares. The shares began vesting on March 12, 2020 and shall vest in equal monthly installments until February 12, 2024.
Footnote F4
The option was granted on March 11, 2021 for 35,752 shares. The shares underlying the option began vesting on April 1, 2021 and shall vest in equal monthly installments thereafter until March 1, 2025.